Examining the effects of magnesium replacement in hospitalized patients with low magnesium levels
Magnesium Deficiency In Patients Hospitalized in Internal Medicine Wards
This study is testing if giving magnesium supplements to hospitalized patients with low magnesium levels can help them recover better and stay in the hospital for a shorter time.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 330 (estimated) |
| Ages | 18 Years to 90 Years |
| Sex | All |
| Sponsor | HaEmek Medical Center, Israel Academic / other |
| Locations | 1 site (Afula) |
| Trial ID | NCT03088852 on ClinicalTrials.gov |
What this trial studies
This study investigates the impact of magnesium replacement therapy on patients hospitalized with hypomagnesemia, a condition characterized by low magnesium levels. It aims to determine whether administering magnesium citrate can improve patient outcomes, including mortality rates and length of hospital stay. The study will involve patients over 18 years old who have been diagnosed with hypomagnesemia and are able to provide consent. The intervention consists of giving magnesium citrate for several months to replenish magnesium stores.
Who should consider this trial
Good fit: Ideal candidates are hospitalized patients over 18 years old with hypomagnesemia who can provide consent.
Not a fit: Patients who are critically ill, on dialysis, or have severe malnutrition may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved recovery and reduced mortality for patients with low magnesium levels.
How similar studies have performed: Previous studies have indicated that magnesium deficiency is linked to poor outcomes, but this specific approach to treatment is less commonly tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Any patient admitted over the age of 18, has hypomagnesemia (magnesium level ≤1.9 mg/dL) and is able to give consent. Exclusion Criteria: * A patient unable to give consent. * A patient admitted for an elective procedure. * A patient in critical condition or dying. * Patients with advanced kidney disease with eGFR\<15ml/min or on dialysis. * Patients with severe diarrhea, precluding use of magnesium citrate. * Patients already receiving magnesium supplements. * Patients with severe malnutrition or life-threatening hypomagnesemia (serum level \<1mg/dL), requiring intravenous and oral replacement of magnesium.
Where this trial is running
Afula
- Emek Medical Center — Afula, Israel (Recruiting)
Study contacts
- Principal investigator: Frieda Wolf — haemek medical center
- Study coordinator: Frieda Wolf
- Email: friedawo@clalit.org.il
- Phone: 972-4-6495476
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.